OverviewSuggest Edit

Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes. 

TypePublic
Founded1992
HQIrvine, US
Websiteendologix.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2018)528(-21%)
Job Openings12
Revenue (FY, 2018)$156.5 M(-13%)
Share Price (Oct 2019)$3.7 (+4%)

Key People/Management at Endologix

John Onopchenko

John Onopchenko

CEO
Vaseem Mahboob

Vaseem Mahboob

CFO
Michael Chobotov

Michael Chobotov

Chief Technology Officer
Matthew Thompson

Matthew Thompson

Chief Medical Officer
Meg Carr

Meg Carr

Vice President, Regulatory
Joseph A. DeJohn

Joseph A. DeJohn

Vice President, International Sales
Show more

Endologix Office Locations

Endologix has offices in Irvine and Rosmalen
Irvine, US (HQ)
2 Musick
Rosmalen, NL
40 Burgemeester Burgerslaan
Show all (2)

Endologix Financials and Metrics

Endologix Revenue

Embed Graph
View revenue for all periods
Endologix's revenue was reported to be $156.47 m in FY, 2018 which is a 13.6% decrease from the previous period.
USD

Revenue (Q2, 2019)

36.2m

Gross profit (Q2, 2019)

23.0m

Gross profit margin (Q2, 2019), %

63.4%

Net income (Q2, 2019)

(27.1m)

EBIT (Q2, 2019)

(9.9m)

Market capitalization (11-Oct-2019)

64.4m

Closing stock price (11-Oct-2019)

3.7

Cash (30-Jun-2019)

50.9m
Endologix's current market capitalization is $64.4 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

192.9m181.2m156.5m

Revenue growth, %

26%(6%)(14%)

Cost of goods sold

69.1m59.8m64.6m

Gross profit

123.8m121.3m91.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

42.6m48.6m46.0m42.3m44.7m34.8m35.6m36.2m

Cost of goods sold

14.0m16.3m16.9m14.0m15.1m12.1m12.4m13.3m

Gross profit

28.6m32.2m29.1m28.3m29.6m22.6m23.2m23.0m

Gross profit Margin, %

67%66%63%67%66%65%65%63%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

26.1m58.0m23.5m

Accounts Receivable

1.8m

Inventories

41.2m45.2m30.4m

Current Assets

129.8m143.1m78.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

15.5m81.6m74.6m48.0m35.6m38.3m9.7m50.9m

Accounts Receivable

952.0k390.0k

Inventories

42.7m43.6m42.7m45.8m42.8m42.3m30.2m30.7m

Current Assets

113.0m175.8m157.9m128.7m115.9m110.1m70.0m107.4m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(154.7m)(66.4m)(79.7m)

Depreciation and Amortization

9.1m9.1m8.0m

Inventories

3.5m(3.0m)13.8m

Accounts Payable

(5.2m)(1.8m)(1.3m)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(21.3m)(37.6m)(51.9m)(19.8m)(43.6m)(53.8m)(22.0m)(49.2m)

Depreciation and Amortization

2.3m4.6m6.9m2.0m3.9m5.9m1.7m3.5m

Inventories

(1.5m)(2.2m)(1.0m)(784.0k)1.8m2.1m112.0k(463.0k)

Accounts Payable

(4.5m)(3.5m)(3.4m)391.0k809.0k(1.0m)5.4m1.7m
USDY, 2019

Financial Leverage

4.5 x
Show all financial metrics

Endologix Online and Social Media Presence

Embed Graph

Endologix News and Updates

Endologix Blogs

Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

The post Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants appeared first on Endologix.

Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

The post Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications appeared first on Endologix.

Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

The post Endologix Honors Innovators of Aortic Therapy at VEITHsymposium appeared first on Endologix.

FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall

The post FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall appeared first on Endologix.

Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range

The post Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range appeared first on Endologix.

Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

The post Endologix Appoints Jeffrey S. Brown as Chief Operations Officer appeared first on Endologix.

Endologix Frequently Asked Questions

  • When was Endologix founded?

    Endologix was founded in 1992.

  • Who are Endologix key executives?

    Endologix's key executives are John Onopchenko, Vaseem Mahboob and Michael Chobotov.

  • How many employees does Endologix have?

    Endologix has 528 employees.

  • What is Endologix revenue?

    Latest Endologix annual revenue is $156.5 m.

  • What is Endologix revenue per employee?

    Latest Endologix revenue per employee is $296.4 k.

  • Who are Endologix competitors?

    Competitors of Endologix include U.S. Stem Cell, Cannabis Sativa and Vital Therapies.

  • Where is Endologix headquarters?

    Endologix headquarters is located at 2 Musick, Irvine.

  • Where are Endologix offices?

    Endologix has offices in Irvine and Rosmalen.

  • How many offices does Endologix have?

    Endologix has 2 offices.